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Abstract
Background: Transcatheter aortic valve implantation via the transfemoral route (TF-TAVI) is commonly performed as a
treatment for severe aortic stenosis (AS) in patients at high surgical risk. Pre-deployment balloon aortic valvuloplasty
(BAV) has generally been considered an essential step for preparing the valve landing zone for receipt of the prosthesis.
However, there is little evidence supporting the clinical value of BAV, while several associated complications have been
documented. This has provoked several groups to evaluate the feasibility and safety of omitting BAV form the TF-TAVI
procedure (direct TF-TAVI), with encouraging results. However, studies comparing the clinical outcomes of direct
TF-TAVI to standard TF-TAVI are lacking.
Methods: EASE-IT TF is a prospective, observational, two-armed, multicentre registry designed to gather data on
procedural aspects, adverse events and survival rates associated with direct TF-TAVI using the Edwards SAPIEN 3
balloon-expandable prosthesis.
Discussion: EASE-IT-TF data will be analysed firstly to determine the risks and benefits associated with direct TF-TAVI
vs. standard TF-TAVI, and secondly to identify associations between patient variables and specific outcomes. This may
assist identification of patients who stand to benefit from direct TF-TAVI, therefore contributing to clinical reductions in
TF-TAVI-associated morbidity and mortality rates in high-risk AS patients.
Trial registrations: Clinictrials.gov: NCT02760771
Keywords: Transcatheter aortic valve implantation, Transfemoral, EASE-IT, Balloon aortic valvuloplasty (BAV), Direct TAVI,
Edwards SAPIEN
Background
Until recently, pre-dilation of the stenosed aortic valve
using an expandable balloon (pre-deployment balloon
aortic valvuloplasty; BAV) has been deemed an essential
step for facilitating the crossing of the aortic annulus,
reducing radial counterforce, and permitting greater pros-
thetic heart valve (PHV) expansion during transcatheter
aortic valve implantation (TAVI) [1], though there is little
proof of this in the literature. BAV may also permit early
evaluation of cusp positioning, calcification, and the
potential for balloon slippage during the successive valve
landing [2]. Conversely, there are several problems associ-
ated with BAV, including transient coronary, cerebral, and
renal ischemia, haemodynamic instability and systemic
inflammatory response syndrome as a result of the need
for rapid ventricular pacing (>180 bpm for up to 30 s) [2];
conduction disturbances requiring permanent pacemaker
implantation (PPI) [3, 4]; coronary occlusion; tamponade;
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profound hypotension; aortic regurgitation; and displace-
ment of fragments from the valve increasing stroke
risk [4–7]. With this in mind, modification of the
TAVI procedure to omit the BAV step has been
investigated in several clinical studies for a variety of
access routes, and generally demonstrated to be feas-
ible and safe without compromising procedural suc-
cess [1, 5, 8–14].
Several pilot studies in high surgical risk patients
undergoing TF-TAVI without prior BAV (direct
TF-TAVI) have been published to date. An early pilot
study by Grube et al. in 60 consecutive patients under-
going direct TF-TAVI with the Medtronic CoreValve
PHV described a 96.7 % procedural success rate, with
in-hospital mortality, stroke, major vascular complica-
tion, and myocardial infarction (MI) rates of 6.7, 5, 10,
and 0 %, respectively [1]. Concurrently, a similar pilot
study by Mendiz et al. using the same PHV demon-
strated that direct TF-TAVI in 51 patients led to a pro-
cedural success rate of 94.2 %, with PPI, stroke and
all-cause mortality rates of in 27.5, 3.9, and 3.9 % at
30 days [11]. Most recently, a larger retrospective study
enrolling 163 patients found that direct TF-TAVI with
the SAPIEN 3 PHV was feasible in 94.5 % of cases, and
had an all-cause mortality rate of 3.7 % at 30 days [10].
BAV was required to overcome crossing difficulties in
only 5.5 % of patients, who were generally older, had a
higher calcium score, higher transvalvular gradients, and
smaller AVA. Thus, pilot studies have demonstrated the
feasibility of direct TF-TAVI in the majority of standard
TF-TAVI candidates; though suggest that further studies
to identify characteristics of patients for whom the tech-
nique is most appropriate would be useful.
Early, small comparative studies found that compared to
standard TF-TAVI, direct TF-TAVI resulted in higher suc-
cess rates (85 % vs. 64 %), a significantly lower incidence
of moderate-to-severe paravalvular leak (9 % vs. 33 %)
[12], reduced radiation dosage (42.0 vs. 56.6 Gy cm2), and
reduced contrast agent volume (92.2 vs. 112 mL) [13].
Bijkulic et al. found, guided by diffusion-weighted magnetic
resonance imaging, that the implantation of a balloon-
expandable aortic valve without versus with prior BAV,
although performed with a shorter procedure time and
lower contrast volume, is associated with a significantly
higher volume of cerebral ischemic lesions [15]. A later,
case-matched analysis in 52 patients using Edwards
SAPIEN PHVs found no significant difference between dir-
ect TF-TAVI and standard TF-TAVI in terms of success
rate (96.2 % vs. 92.3 %), all-cause mortality at 30 days (both
7.7 %), disabling stroke (3.8 % vs. 7.7 %) or moderate-severe
paravalvular leak (0 % vs. 7.7 %); though did document
significantly lower procedural times (60 vs. 70 min), fluor-
oscopy time (13.3 vs. 17.8 min), and contrast agent volume
(118.7 vs. 153.0 mL) for direct TF-TAVI [8]. However, the
insufficient statistical power and unsatisfactory study design
of the aforementioned studies prevent firm conclusions
being drawn. One larger study by Islas et al. in 249 con-
secutive patients undergoing TF-TAVI was published
recently, and found that direct TAVI resulted in signifi-
cantly shorter procedural durations (108.5 vs. 133.7 min),
reduced rates of PPI (6.3 % vs. 14.1 %), procedure-related
mortality, and 30-day mortality (both 2.5 % vs. 11.8 %) [16].
While these results are encouraging, it should be noted that
group assignment was based on pre-defined transesopha-
geal echocardiographic criteria potentially biasing patient
populations, the study was monocentric, and employed two
different PHVs (only 106 patients received the Edwards
SAPIEN PHV and 143 patients the CoreValve). Thus, find-
ings should be interpreted with care. Considered together,
early comparative studies suggest that direct TF-TAVI may
offer several advantages over standard TF-TAVI, though
carefully designed, multi-centric, large-cohort studies are
clearly required.
To the best of our knowledge, no large registry, fully-
prospective studies comparing direct TF-TAVI to standard
TF-TAVI with the Edwards SAPIEN PHVs have been pub-
lished to date. We have therefore designed a two-armed,
controlled-cohort, observational, multicentre registry
(EASE-IT TF) to investigate the clinical implications of
BAV in TF-TAVI using the balloon expandable Edwards
SAPIEN 3 PHV. Data on procedural aspects, adverse
events and mortality will be used to identify differences in
operative outcomes when BAV is performed or omitted.
Possible associations between patient variables and these
outcomes will then be identified.
Methods/design
This prospective, non-randomised, non-interventional
controlled cohort study evaluating the safety and efficacy
of the Edwards SAPIEN 3 PHV in standard TF-TAVI vs.
direct TF-TAVI is based on EASE-IT TF: a two-armed,
observational registry containing data from 10 German
sites. Ethic committee approval was obtained from the
appropriate ethics committee in writing prior to patient
an enrolment. We aim to enrol and average of 20
patients per site, generating a minimum study popula-
tion of 200. All patients are required to provide a signed
informed consent form (ICF) prior to enrolment.
Site selection
Selected sites must have prior experience of TF-TAVI
implantations and the proven capacity to enrol at least 2
patients per month. Additionally, independently of inclu-
sion in the registry, all participating sites must have
received the following training for implantation of the
Edwards SAPIEN 3: 1) instructions for use (IFU)
provided by the manufacturer, 2) exhaustive fundamen-
tals training (i.e., device preparation, didactic sessions,
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simulator training and case observations), and 3) on-site
training as per the Edwards Standard Operating
Procedure.
Patient selection
In order to be included in the study, patients are required
to meet all of the following criteria: 1) indication for TF-
TAVI according to the IFU for the Edwards SAPIEN 3
PHV, 2) age ≥18 years, 3) signed ICF. All patients meeting
any of the following criteria will be excluded from the
study: 1) contraindications for TAVI via the TF access
route according to the Edwards SAPIEN 3 IFU, 2) logistic
Euro-SCORE I >40 %, 3) mitral or tricuspid valvular insuf-
ficiency > grade II, 4) uncontrolled atrial fibrillation (no
rhythm control established), 5) left ventricular or atrial
thrombus identified via echocardiography, 6) previous
aortic valve replacement, 7) mobile structures on leaflets,
8) requirement for a cerebral protection device, and 9)
high probability of non-adherence to follow-up require-
ments based on social, psychological or medical grounds.
So as to avoid influencing investigator decision to perform
TF-TAVI with or without BAV, enrolment in the register
will occur after this choice had already been made, and a
1:1 ratio will not be strictly pursued (Fig. 1). Reasons for
this decision and any subsequent changes will be system-
atically documented. Subjects withdrawing consent will be
omitted from the registry and not replaced.
TF-TAVI procedure
Investigators are free to perform TF-TAVI using the
Edwards SAPIEN 3 PHV according to locally-adopted
techniques. Patients in the standard TF-TAVI group will
undergo the procedure with pre-deployment BAV, while
those in the direct TF-TAVI group will undergo the pro-
cedure without pre-deployment BAV.
Outcome measures
The primary outcome measure is the combined rate of
all-cause mortality, stroke, non-fatal MI, acute kidney
injury (AKI), and PPI between commencement of
the TAVI procedure and 30 days (±7 days) post-
intervention. Secondary outcome measures are each
of the aforementioned factors making up the primary out-
come considered separately at 30 days (±7 days) and
6 months (±16 days) post-TAVI, procedure time, duration
of radiation exposure, volume of contrast agent used, and
rate of aortic root rupture. A further secondary outcome
measure is the combined rate of all-cause mortality,
stroke, non-fatal MI, AKI, and PPI up to 6 months
(±14 days) post-TAVI.
Data collection
Data on enrolled patients will be collected via electronic
case report forms (eCRFs) using registry identification
numbers rather than names, to protect identity. eCRFs
will be completed for the visit prior to implantation, on
the day of implantation, and at follow-up visits 30 ±
7 days and 6 months (±14 days) post-implantation, and
signed at the earliest opportunity by either the investiga-
tor or designated responsible party (Table 1). The results
of pre-TAVI echo and CT assessment will be docu-
mented as well as potential reasons for or against opting
for BAV in a given patient. Additionally, reports of
device-related serious adverse events or death must be
provided within 48 h of occurrence. Up to 2 sites (20 %)
will be randomly selected for monitoring purposes
following completion of data collection, and subjected to
source data verification (expected to be 100 % for stroke,
life-threatening or major bleeding, renal failure, vascular
and valve complications, PPI and mortality).
Fig. 1 Diagram of registry design, procedures and stages
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Statistics
To achieve a statistical power of 80 %, the estimated
sample size needed to detect an absolute risk reduction
of 13 % at 30 days post-TAVI was 180 evaluable patients.
This calculation was based on the 30-day event rates
reported by a previous study on direct TF-TAVI by
Grube et al. [1]. In order to accommodate an approxi-
mate drop out rate of 10 % (20 patients) during the first
30 days, a final necessary sample size of 200 patients
was established.
Analysis for all patients in the registry will be per-
formed from an intention-to-treat perspective. The
collected data will be presented and summarised using
descriptive statistics. Categorical variables will be
reported as frequency distributions, while continuous
variables will be reported as mean (± standard deviation)
and median (range) values. Where appropriate, actuarial
probability and linearised rates may be used to report on
adverse events. Survival (and adverse event outcomes,
where appropriate) will be analysed using the Kaplan-
Meier method.
Discussion
The present registry-based controlled cohort study
(EASE-IT TF) aims to assess the procedural and clinical
outcomes of TF-TAVI with the Edwards SAPIEN 3 PHV
when BAV is performed, compared to when the BAV step
is omitted. Analysis of the resulting data should provide
insight into the clinical relevance and value of BAV in TF-
TAVI, and also reveal possible patient variables associated
with different outcomes. These findings will have several
notable implications for clinical practise.
Despite a number of groups reporting the feasibility
and safety of direct TF-TAVI with the Edwards SAPIEN
PHV [8, 10, 13, 16], the relative impact of this technique
on clinical outcomes has not been properly verified due
to methodological limitations of existing comparative
studies. As a well-designed, two-arm, fully-prospective,
real-world registry, EASE-IT TF will shed light on the
potential for direct TF-TAVI to reduce the incidence of
the most eminent serious adverse events currently facing
TF-TAVI patients. Most notably, these include stroke,
AKI, MI, conduction disturbances requiring permanent
PPI, and mortality.
Stroke has been previously identified as a predictor of
early and medium-term mortality in TAVI patients [17].
It is thought that stroke during TAVI occurs due to
dislodgement of embolic fragments from the valve and
access vessels caused by the extensive movement of
catheters and guide wires, BAV, and PHV expansion. In
a study by Reinsfelt et al. using intraoperative transcra-
nial Doppler imaging, 282 cerebral microembolic signals
(MES) were recorded in patients undergoing routine
TAVI, of which 37 % were generated during instrumen-
tation and 22 % during BAV [18]. A similar Doppler-
based study by Erdoes et al. detected a median of 580
intraoperative cerebral high-intensity transient signals
(HITS) in TF-TAVI patients, with 28 % generated during
instrumentation and 11 % during BAV [7]. A further
study by Drews et al. detected medians of 435 and 471
Table 1 Assessments
Parameter Admission Intervention Discharge 30d FU 6 Mo FU
Inclusion/Exclusion criteria X
Demographics X
Diagnosis of valve disease X
Echocardiography X
Computed Tomography X
Symptoms X X X




Prior cardiovascular intervention X
Current medications X X X X
Interventional details X
Interventional results X
AE X X X X
Hospitalization duration X
Creatinine value X X X
Early safety/Clinical efficacy X X
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HITS and 78 and 62 MES in the right and left middle
cerebral arteries of TAVI patients, respectively, with par-
ticular peaks during BAV and PHV positioning [6].
These studies suggest that elimination of BAV from the
TAVI procedure (thereby also reducing instrument
manipulation) may reduce stroke risk, and potentially
minimise other thromboembolic outcomes such as MI.
EASE-IT TF will be valuable for testing this hypothesis.
A frequently observed clinical complication of TAVI is
AKI, which has been documented in around 16 % of
patients and is associated with poor prognosis [19–22].
One factor that may contribute to AKI is the volume of
contrast agent used. Van Linden et al. reported a signifi-
cant correlation between intraoperative contrast agent
volume and postoperative AKI in 270 consecutive
patients undergoing TA-TAVI with the Edwards SAPIEN
PHV [22]. In particular, use of >99 ml of contrast agent
was an independent predictor of AKI. Concurrently, a
study by Yamamoto et al. in a cohort of 415 elderly
TF-TAVI patients found that subjects experiencing post-
procedural AKI had been exposed to greater contrast
agent doses, and multivariate analysis confirmed the
association [21]. Furthermore, a study by Madershahian
et al. including 50 patients with pre-existing renal im-
pairment undergoing TA-TAVI with the Edwards
SAPIEN PHV found a significantly greater prevalence of
acute contrast-induced nephropathy in patients receiving
>100 mL contrast agent compared to those receiving
<100 mL (69.2 % vs. 41.7 %, respectively) [23]. It there-
fore appears that reducing contrast agent volume may
reduce AKI rates. Importantly, several studies report that
direct TAVI significantly reduces contrast agent volumes
[8, 13], indicating the potential for this to translate into
reduced AKI. Again, results from the EASE-IT TF regis-
try will help to clarify this idea.
Conduction disturbances requiring PPI have been
reported to occur in 13–25 % of patients undergoing
TAVI [3, 24]. In PARTNER, patients requiring PPI had
longer postoperative hospitalisation times (7.3 days vs.
6.2 days), higher frequencies of repeat hospitalisations
up to 1 year (23.9 % vs. 18.2 %) and increased mortality
or repeat hospitalisation up to 1 year (42.0 % vs. 32.6 %)
[25]. Therefore, reducing PPI requirement is clearly
desirable. In a study by Gensas et al., BAV was identified
as an independent predictor of PPI requirement [3].
Concurrently, findings by Grube et al., Fiorina et al. and
Islas et al. suggest that PPI rate is lower in patients
undergoing direct TF-TAVI compared to standard TF-
TAVI (11.7 % vs. 27.8 %, 5.5 % vs. 15.5 %, and 6.3 % vs.
14.1 %, respectively). Conversely, Conradi et al. found no
significant difference in PPI rate between the two pro-
cedural variants (both 15.4 %). Therefore, the effect of
BAV on PPI requirement requires additional investiga-
tion, which the EASE-IT TF study will provide.
In addition to identifying potential benefits, the EASE-
IT TF study may also reveal negative outcomes associ-
ated with direct TF-TAVI. These may include the need
for post-procedural BAV, which has already been noted
in 16.7–34 % of patients undergoing direct TF-TAVI
with the CoreValve PHV [1, 11, 12] and 0–13.7 % of
patients with an Edwards SAPIEN PHV [8, 13, 16]. Data
gathered in EASE-IT TF will provide additional com-
parative evidence on this, and other complications of
direct TF-TAVI.
Taking everything into account, EASE-IT TF should
provide invaluable information from which to make
well-informed recommendations about the costs/bene-
fits of performing BAV in TF-TAVI. The planned
analysis to identify specific patient characteristics associ-
ated with more or less favourable outcomes (for ex-
ample, exclusion of BAV is associated with reduced AKI
rate in patients with existing kidney disease, while detri-
mental in patients with reduced left ventricular ejection
fraction) has the potential to offer valuable insight into
the appropriateness of BAV in distinct patient subsets.
In terms of future developments within the field, EASE-
IT TF will promote critical consideration of the
currently adopted TAVI method, and may lead to refine-
ment of technical guidelines.
Potential limitations of EAE-IT TF
As an observational study, EASE-IT TF is extremely use-
ful for providing real-world information that is directly
applicable to clinical practise, but has several potential
limitations. Firstly, physicians are free to place patients
in either direct TF-TAVI or standard TF-TAVI groups at
their discretion, which may mean more patients with a
certain characteristic (i.e., higher Euro-SCORE) are con-
centrated in a particular group. This lack of randomisa-
tion may produce distinct study arm populations,
limiting validity of subsequent inter-group comparisons.
However, this is unavoidable if we wish to assess the
benefits of direct TF-TAVI in patients that physicians
consider eligible in the real world. By asking investiga-
tors to justify their decision, we gain valuable informa-
tion about the criteria currently deemed indicative for
TF-TAVI with or without BAV. This will enable us to
reflect upon the reliability of these factors for determin-
ing direct TF-TAVI eligibility, and provide further
recommendations. Secondly, the fact that a 1:1 group
assignment ratio is not obligatory may result in smaller
patient numbers in one study arm, potentially reducing
statistical power. Again, this is an inherent and unavoid-
able problem when examining real-world circumstances.
Thirdly, compared to most clinical trials, observational
registry data tends to contain more omissions and inac-
curacies. However, monitoring following database
closure is planned, and will ensure verification of source
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data in a reasonable sample of enrolled patients to
minimise this limitation. Finally, only a 6-month follow-
up is planned, which may be inadequate to detect the
effect of direct TF-TAVI on long-term outcomes. Fur-
ther studies may therefore be required to evaluate these
long-term consequences. Though essential for validity,
the use of a single PHV type (Edward SAPIEN 3) in
EASE-IT TF means that findings will be limited to TF-
TAVI with this specific device. Therefore, further studies
assessing the clinical value of BAV using other PHVs will
be necessary. The same is true for alternative delivery
systems, access routes and patient groups.
Conclusions
The large-cohort EASE-IT-TF study will generate important
data regarding rates of procedural success, adverse events,
and mortality associated with omitting BAV from the
standard TF-TAVI procedure. This information will be used
to determine the risks and benefits associated with direct
TAVI, which may then be applied to clinical practise for the
identification of appropriate patients. In this way, EASE-IT
TF will contribute to reductions in morbidity and mortality
rates associated with TAVI in high-risk AS patients.
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